111 related articles for article (PubMed ID: 14682340)
1. Bring back the acetyls - a novel anticancer movement.
Melton L
Lancet Oncol; 2003 Dec; 4(12):710. PubMed ID: 14682340
[No Abstract] [Full Text] [Related]
2. Anticancer drug shows promise against lupus.
Foubister V
Drug Discov Today; 2003 Apr; 8(8):333-4. PubMed ID: 12681930
[No Abstract] [Full Text] [Related]
3. Molecule of the month. Vorinostat.
Drug News Perspect; 2006; 19(6):352. PubMed ID: 16971971
[No Abstract] [Full Text] [Related]
4. Early clinical data and potential clinical utility of novel histone deacetylase inhibitors in prostate cancer.
Clin Prostate Cancer; 2005 Sep; 4(2):83-5. PubMed ID: 16197607
[No Abstract] [Full Text] [Related]
5. Vorinostat.
Grant S; Easley C; Kirkpatrick P
Nat Rev Drug Discov; 2007 Jan; 6(1):21-2. PubMed ID: 17269160
[No Abstract] [Full Text] [Related]
6. Histone deacetylase inhibitors: Are they here to stay?
Ibrahim RB
Am J Health Syst Pharm; 2010 May; 67(10):791. PubMed ID: 20479099
[No Abstract] [Full Text] [Related]
7. Vorinostat (Zolinza) for cutaneous T-Cell lymphoma.
Med Lett Drugs Ther; 2007 Mar; 49(1256):23-4. PubMed ID: 17351559
[No Abstract] [Full Text] [Related]
8. Vorinostat approved for rare lymphoma.
Thompson CA
Am J Health Syst Pharm; 2006 Nov; 63(22):2168. PubMed ID: 17090730
[No Abstract] [Full Text] [Related]
9. [Vorinostat in the treatment of cutaneous T-cell lymphomas. Treatment with histone deacetylases inhibitors].
Zirlik K; Nashan D; Veelken H
Pharm Unserer Zeit; 2010 May; 39(3):190-6. PubMed ID: 20425773
[No Abstract] [Full Text] [Related]
10. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
11. Vorinostat in cutaneous T-cell lymphoma.
Duvic M; Vu J
Drugs Today (Barc); 2007 Sep; 43(9):585-99. PubMed ID: 17940636
[TBL] [Abstract][Full Text] [Related]
12. Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma.
Kavanaugh SM; White LA; Kolesar JM
Am J Health Syst Pharm; 2010 May; 67(10):793-7. PubMed ID: 20479100
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma.
Lautz TB; Naiditch JA; Clark S; Chu F; Madonna MB
J Pediatr Surg; 2012 Jun; 47(6):1267-71. PubMed ID: 22703804
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors in cancer therapy.
Fouladi M
Cancer Invest; 2006; 24(5):521-7. PubMed ID: 16939962
[No Abstract] [Full Text] [Related]
15. Belinostat: a new broad acting antineoplastic histone deacetylase inhibitor.
Gimsing P
Expert Opin Investig Drugs; 2009 Apr; 18(4):501-8. PubMed ID: 19335278
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors: novel agents in cancer treatment.
Glass E; Viale PH
Clin J Oncol Nurs; 2013 Feb; 17(1):34-40. PubMed ID: 23372094
[TBL] [Abstract][Full Text] [Related]
17. [Progress in cancer treatment with histone deacetylase inhibitor].
Dong M; Hu XS; Chen SS; Xing PY; Feng FY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2013 Jul; 35(7):481-5. PubMed ID: 24257296
[No Abstract] [Full Text] [Related]
18. Treatment of cutaneous T-cell lymphoma: focus on vorinostat.
Heymann WR
J Am Acad Dermatol; 2008 Oct; 59(4):696-7. PubMed ID: 18793938
[TBL] [Abstract][Full Text] [Related]
19. Panobinostat (Farydak) for multiple myeloma.
Med Lett Drugs Ther; 2015 Aug; 57(1475):e118-9. PubMed ID: 26262884
[No Abstract] [Full Text] [Related]
20. The novel histone deacetylase inhibitor NVP-LAQ824: an addition to the therapeutic armamentarium in leukemia?
Grant S
Leukemia; 2004 Dec; 18(12):1931-3. PubMed ID: 15496978
[No Abstract] [Full Text] [Related]
[Next] [New Search]